Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Free Report) insider Carmen Jeffrey Del sold 7,541 shares of the company’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $16.07, for a total transaction of $121,183.87. Following the completion of the sale, the insider now owns 18,427 shares of […]
Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Rating) had its price objective lifted by Truist Financial from $22.00 to $24.00 in a research report report published on Tuesday morning, The Fly reports. A number of other research firms have also weighed in on CPRX. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a hold rating to a buy […]
StockNews.com upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Rating) from a hold rating to a buy rating in a report published on Thursday. Separately, Cantor Fitzgerald boosted their price objective on Catalyst Pharmaceuticals from $22.00 to $25.00 in a research note on Friday, March 17th. One investment analyst has rated the stock with a […]
JW Asset Management LLC acquired a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Rating) during the 4th quarter, HoldingsChannel reports. The firm acquired 563,392 shares of the biopharmaceutical company’s stock, valued at approximately $10,479,000. Catalyst Pharmaceuticals makes up 4.3% of JW Asset Management LLC’s investment portfolio, making the stock its 2nd biggest holding. […]
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Rating) – Research analysts at HC Wainwright lowered their Q2 2023 earnings estimates for shares of Catalyst Pharmaceuticals in a report released on Friday, May 12th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will post earnings per share of $0.27 for the quarter, down from […]